PV is aimed at increasing the visibility and suspiciousness of malignant lesions, but in our study the perceived suspiciousness of benign lesions and normal cases is increased as well.
All malignant and benign cases were confirmed by biopsy or surgery, and normal cases were confirmed by 2-y follow-up.
Among those cases were 206 malignant, 486 benign and 308 normal cases.
Prostate cancer cells exhibited a pronounced global decrease in methylation compared with benign and normal tissue.
The usefulness of E2F5, CA125, and their combinations as diagnostic markers to differentiate normal cases, benign, early and late malignant tumors were assessed using ROC analysis with sensitivity, specificity, positive & negative predictive values (PPV & NPV) presented.
The cases were divided over five diagnostic categories: adenocarcinoma (cancer, 2 cases), adenoma (pre-stage of cancer, 2 cases), inflammation (1 case), hyperplastic polyp (benign polyp, 1 case), and normal tissue (1 case).
Data were examined from three recent rounds of the PERFORMS breast screening self-assessment scheme (that is, three sets of 120 difficult normal, benign and malignant FFDM cases) that had respectively been reported by 723, 726 and 687 breast radiologists and advanced practitioners in order to determine the error rates and the underlying reasons for such errors.
Samples from 86 malignant (75 cases for genome-wide methylation analysis), 20 benign and 6 normal epithelial ovarian tissues were collected during surgery, frozen immediately in liquid nitrogen and stored at -80°C or in liquid nitrogen until analysis.
